Prostate Cancer

New test may significantly enhance prostate cancer evaluation

For men newly diagnosed with prostate cancer or patients previously treated, the risk of metastasis is a crucial determinant of whether to choose conservative management or undergo further treatment. For prostate as well as other cancers, primary tumor growth or spread is driven by amplifications or deletions of portions of the genome known as copy number alterations (CNAs). A report in The Journal of Molecular Diagnostics describes a new assay to assess CNAs that is cheaper, faster, reproducible, and requires less tissue than other diagnostic techniques and has the potential to significantly enhance prostate cancer evaluation. Metastases occur in approximately 16 percent of prostate cancers and account for 8 percent of all male cancer deaths. Accurate prediction at the time of diagnosis can identify [...]

2018-12-18T08:37:55-07:00December 18th, 2018|

Study discovers link between inflammatory bowel disease and prostate cancer

. Men with inflammatory bowel disease have four to five times higher risk of being diagnosed with prostate cancer, reports a 20-year study from Northwestern Medicine. This is the first report to show men with inflammatory bowel disease have higher than average PSA (prostate-specific antigen) values, and this group also has a significantly higher risk of potentially dangerous prostate cancer. About 1 million men have inflammatory bowel disease in the U.S. Inflammatory bowel disease is a common chronic condition that includes Crohn's disease and ulcerative colitis. "These patients may need to be screened more carefully than a man without inflammatory bowel disease," said lead study author Dr. Shilajit Kundu. "If a man with inflammatory bowel disease has an elevated PSA, it may be an [...]

2018-12-11T08:37:12-07:00December 11th, 2018|

Understanding Prostate Screening & Treatment Options

For some types of cancer, screening can help find cancers at an early stage, when they are more likely to be easier to treat. According to the American Cancer Society, prostate cancer can often be found before symptoms arise by testing the amount of prostate-specific antigen (PSA) in a man’s blood. Another way to find prostate cancer is the digital rectal exam (DRE), in which the doctor puts a gloved, lubricated finger into the rectum to feel the prostate gland. If the results of either one of these tests are abnormal, further testing is often done to see if a man has cancer. If prostate cancer is found as a result of screening with the PSA test or DRE, it will probably be at [...]

2018-11-26T10:28:35-07:00November 26th, 2018|

New study looks to determine type of prostate cancer — dangerous or manageable

Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy. A recent study showed that more than 25 men were being unnecessarily treated with surgery or radiotherapy, for every single life saved. It is believed that success rates could be hindered as a result of treating all prostate cancers in the same way. A team at the University of York and the University of British Columbia, Canada, however, have designed a test that can pick out life-threatening prostate cancers, with up to 92% accuracy. Professor Norman Maitland, from the University of York's Department of Biology, said: "Unnecessary prostate treatment has both physical consequences for patients and their families, [...]

2018-11-20T07:52:53-07:00November 20th, 2018|

Scientists take step towards identifying management of prostate cancers

Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy. A recent study showed that more than 25 men were being unnecessarily treated with surgery or radiotherapy, for every single life saved. It is believed that success rates could be hindered as a result of treating all prostate cancers in the same way. A team at the University of York and the University of British Columbia, Canada, however, have designed a test that can pick out life-threatening prostate cancers, with up to 92% accuracy. Professor Norman Maitland, from the University of York's Department of Biology, said: "Unnecessary prostate treatment has both physical consequences for patients and their families, [...]

2018-11-06T07:32:36-07:00October 23rd, 2018|

Commonality found between lung and prostate cancers

UCLA researchers have discovered a common process in the development of late-stage, small cell cancers of the prostate and lung. These shared molecular mechanisms could lead to the development of drugs to treat not just prostate and lung cancers, but small cell cancers of almost any organ. The key finding: Prostate and lung cells have very different patterns of gene expression when they're healthy, but almost identical patterns when they transform into small cell cancers. The research suggests that different types of small cell tumors evolve similarly, even when they come from different organs. The study, led by Dr. Owen Witte, founding director of the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research and professor of microbiology, immunology and [...]

2018-10-09T09:22:01-07:00October 9th, 2018|

Scientists discover hormone therapy’s impact on prostate cancer

Scientists at Cedars-Sinai have discovered how prostate cancer can sometimes withstand and outwit a standard hormone therapy, causing the cancer to spread. Their findings also point to a simple blood test that may help doctors predict when this type of hormone therapy resistance will occur. Prostate cancer is the second-leading cause of cancer death in men, behind lung cancer, killing nearly 30,000 in the U.S. each year, according to the American Cancer Society. In its early stages, the most common type, adenocarcinoma, is curable and generally responds well to therapies, including those that target androgen -- a male sex hormone that stimulates tumor growth. However, in certain patients, the cancer becomes resistant to androgen-targeted therapy, and the cancer recurs or spreads. One possible reason [...]

2018-09-11T09:01:12-07:00September 11th, 2018|

Dr. Michael Lazar New Radio Interview on Here’s to Your Health

HIFU is an FDA approved precise and targeted therapy that reduces the risk of complications caused by surgery and radiation. HIFU uses ultrasound energy, or sound waves, to heat and destroy specifically targeted areas of tissue. During HIFU, the sound waves pass through healthy tissue without causing damage. However, at the focal point of the sound waves (like a magnifying glass focusing the rays of the sun to burn a leaf), the tissue temperature is raised to 90 degrees Celsius, destroying the targeted tissue. Men treated with HIFU wake up and go home without pain or bleeding.  They are able to travel the same day, drive the next day, and resume normal activities within a few days.  Those with office based jobs [...]

2018-08-01T08:23:00-07:00August 1st, 2018|

New Study Shows HIFU for Prostate Cancer Yields Excellent Cancer Control

New 5-Year Sonablate® Study Shows Focal HIFU for Prostate Cancer Yields Excellent Cancer Control with Minimal Side Effects HIFU Prostate Services, the largest provider of HIFU Services in US is pleased to announce an Extensive Multicenter Research Study that Demonstrates Sonablate® HIFU Outcomes are Equivalent to Surgery While Maintaining Urinary Continence and Erectile Function Charlotte, N.C. (July 6, 2018) – A 5-year multicenter study following focal therapy for prostate cancer, with the Sonablate HIFU technology, has been published and shows it is possible to achieve whole-gland equivalent cancer control rates without the side effects seen with whole gland treatments. The data demonstrated that focal Sonablate HIFU, or High Intensity Focused Ultrasound, has achieved success rates similar to more traditional prostate cancer surgical procedures [...]

2018-07-24T09:52:11-07:00July 17th, 2018|

Global health insurance company Cigna covers HIFU

Dr. Michael Lazar performing first HIFU surgery on the West Coast at San Francisco Surgery Center --> Cigna, a a global health insurance service company based in the US, announced earlier this year that patients in the United States who have localized radio-recurrent prostate cancer are potentially eligible for insurance coverage for HIFU treatment. In other words, if a man was diagnosed with localized prostate cancer and then had radiation therapy then had the cancer return to the prostate and was diagnosed with localized recurrent prostate cancer, he may be eligible for coverage for having HIFU as a salvage option. It is important to note that coverage is policy specific so it may vary depending on the policy.  More information is available from Cigna [...]

2018-06-19T14:59:20-07:00June 19th, 2018|